Zyban is a sustained‑release prescription medicine used to help adults stop smoking. It works on brain chemicals involved in reward and withdrawal to reduce nicotine cravings and ease symptoms like irritability, low mood, and difficulty concentrating. Unlike nicotine replacement, Zyban contains no nicotine and can be combined with behavioral support or a nicotine patch when medically appropriate. Most people start Zyban one to two weeks before a quit date and continue for at least seven to twelve weeks. Proper screening is essential because Zyban is not suitable for everyone, especially those with seizure risk or specific conditions. Consult your clinician.
Zyban is a smoking cessation aid that helps reduce cravings and withdrawal so you can focus on building a durable quit plan. Its active medicine, a norepinephrine‑dopamine reuptake inhibitor, modulates reward pathways and noncompetitively blocks certain nicotinic receptors, which can blunt the reinforcing effects of cigarettes. Unlike nicotine replacement therapies, Zyban contains no nicotine, and it can be used alone or with counseling, digital tools, and, when appropriate, a nicotine patch. Clinical trials show better quit rates versus placebo, especially when combined with behavioral support. Adults typically start treatment before a target quit date and continue while consolidating new, smoke‑free routines. It may also lessen post‑quit weight gain for some, though lifestyle strategies remain important. Zyban is not a magic bullet; it works best as part of a structured program that includes setting a quit date, managing triggers, and regular follow‑up with a clinician or coach. Support improves long‑term success.
Start Zyban 1 to 2 weeks before your quit date. The usual regimen for adults is 150 mg once daily for 3 days, then increase to 150 mg twice daily, at least 8 hours apart. Do not exceed 300 mg per day for smoking cessation. Swallow sustained‑release tablets whole; do not crush, split, or chew. To minimize insomnia, avoid doses near bedtime and take the second dose in the late afternoon or early evening. Zyban may be taken with or without food; taking with food can reduce stomach upset. A standard course lasts 7 to 12 weeks; some patients benefit from extended therapy up to 6 months to reduce relapse risk. If you are also using a nicotine patch, your clinician may start both together and monitor blood pressure. Dose adjustments or slower titration may be appropriate with hepatic or renal impairment, older age, or sensitivity to stimulatory effects. Do not stop abruptly; set a quit date during the first weeks of treatment. If you have not quit by week 7, reassess strategy with clinician. For adolescents, Zyban is not routinely recommended for smoking cessation. In pregnancy or breastfeeding, risk‑benefit discussion is essential, and non‑pharmacologic supports are prioritized when possible.
Before starting Zyban, tell your clinician about all medical conditions and medicines. Because bupropion lowers the seizure threshold in a dose‑dependent manner, your individual seizure risk must be assessed. Limit or avoid alcohol, and do not abruptly stop alcohol, benzodiazepines, barbiturates, or antiepileptics while taking Zyban. Monitor blood pressure; new or worsened hypertension can occur, especially when combined with nicotine replacement. Sleep disturbance and anxiety are common early; taking doses earlier in the day can help. People with a history of mood disorders should be monitored for changes in behavior, agitation, hypomania/mania, or suicidal thoughts, especially early in treatment and after dose changes. Use caution if you have hepatic or renal impairment, head trauma, eating disorders, diabetes treated with hypoglycemics or insulin, or are taking other drugs that can provoke seizures. Angle‑closure glaucoma can be precipitated in susceptible individuals; seek urgent eye care with eye pain or vision changes. Older adults may be more sensitive to adverse effects. In pregnancy or lactation, weigh smoking‑related risks against medication risks with a clinician experienced in perinatal care. Avoid driving or tasks until you know how Zyban affects concentration. Combine medication with counseling, trigger management, and support to maximize quit rates and durability.
Do not use Zyban if you have a seizure disorder or a current or past diagnosis of bulimia or anorexia nervosa, due to markedly increased seizure risk. Zyban is contraindicated during abrupt discontinuation of alcohol, benzodiazepines, barbiturates, or antiepileptic drugs. Do not take Zyban with monoamine oxidase inhibitors (MAOIs) or within 14 days of stopping an MAOI; serious hypertensive reactions can occur. Avoid concomitant use with other medicines that contain bupropion (for example, Wellbutrin, Aplenzin, Forfivo) to prevent overdose. Hypersensitivity to bupropion or any component of the formulation is a contraindication. Use with caution or alternative therapy in patients with severe hepatic cirrhosis; lower doses and extended intervals are typically required if used at all. Pediatric use is not established.
Like all medicines, Zyban can cause side effects. Common effects include insomnia, dry mouth, headache, nausea, constipation, dizziness, tremor, sweating, ringing in the ears, and changes in taste. Anxiety, restlessness, or irritability may occur early and often improve with time or dose timing adjustments. Some people experience skin rash or itching. Blood pressure can rise, particularly when Zyban is combined with nicotine replacement; monitor regularly if you have hypertension. Less commonly, allergic reactions (hives, facial swelling, difficulty breathing), severe rash (Stevens‑Johnson syndrome), liver injury, visual changes from angle‑closure glaucoma, and psychiatric symptoms such as agitation, confusion, or hallucinations can occur. Seizures are rare at recommended doses but are a serious risk that increases with higher doses or predisposing factors. Seek urgent care for chest pain, severe headache, fainting, palpitations, suicidal thoughts, or any symptom that feels severe, progressive, or unusual. Report bothersome effects to your clinician; simple strategies, timing adjustments, or dose changes may help. If insomnia persists, earlier dosing and avoiding caffeine late in the day may reduce disruption. Dry mouth often improves with sugar‑free gum, water, or saliva substitutes. Nausea can be minimized by taking Zyban with food. Weight changes can occur; plan meals and stay active gradually.
Zyban (bupropion) is a strong inhibitor of CYP2D6. It can raise levels of 2D6‑substrate medicines, including many antidepressants (SSRIs, SNRIs, tricyclics), antipsychotics, beta‑blockers (for example, metoprolol), type 1C antiarrhythmics (propafenone, flecainide), tamoxifen, and others. Dose adjustments or alternative agents may be needed. Avoid monoamine oxidase inhibitors (MAOIs) within 14 days. Use caution with drugs that lower the seizure threshold: other antidepressants, antipsychotics, tramadol, theophylline, systemic corticosteroids, quinolones, mefloquine, cyclobenzaprine, and illicit stimulants. Enzyme inducers such as carbamazepine, phenytoin, phenobarbital, ritonavir, or efavirenz may reduce bupropion exposure, while CYP2B6 inhibitors (ticlopidine, clopidogrel) may increase it. Alcohol can increase neuropsychiatric adverse effects; limit intake and avoid binges. If combining Zyban with nicotine replacement therapy, monitor blood pressure more closely. Herbal products and supplements can also interact; St. John’s wort, kava, and high‑dose caffeine may increase side effects or reduce efficacy. Do not use other bupropion‑containing products concurrently. Always provide your clinician and pharmacist with a full list of prescription medicines, OTC products, and supplements so interactions can be screened and managed proactively. Certain HIV therapies and oncology drugs have interactions; specialist input is recommended. If you take tamoxifen, discuss alternatives because 2D6 inhibition may reduce endoxifen levels. Recheck interactions when medicines change.
If you miss a dose of Zyban, take it as soon as you remember, provided it is at least 8 hours before your next scheduled dose. If it is close to the next dose, skip the missed dose and resume your regular schedule. Do not take extra tablets or double up to make up for a missed dose, as this increases seizure risk. Try to take doses at the same time each day. Setting phone reminders or using a pill organizer can help you stay on track each week, too.
Zyban overdose can be dangerous. Symptoms may include seizures, loss of consciousness, severe agitation, hallucinations, fast or irregular heartbeat, fever, muscle rigidity, vomiting, and low blood pressure. If an overdose is suspected, call emergency services (911 in the U.S.) and, if possible, the Poison Help line at 1‑800‑222‑1222 for immediate guidance. Do not induce vomiting unless directed by professionals. Provide responders with the medication name, strength, approximate amount taken, and the time of ingestion. Treatment is supportive and may include airway protection, seizure management, heart rhythm monitoring, and intravenous fluids. Store tablets securely to prevent accidental ingestion by children or pets. Avoid alcohol and sedatives until medically cleared after overdose.
Store Zyban at room temperature, ideally 20°C to 25°C (68°F to 77°F), in a dry place away from moisture and direct light. Keep tablets in the original, tightly closed container until use. Do not store in the bathroom. Protect from heat and freezing. Keep out of reach of children and pets. Do not use after the expiration date, and dispose of unused tablets through a take‑back program when available locally.
In the United States, Zyban is an Rx‑only medication. Federal and state laws require that a licensed clinician assess eligibility and authorize therapy, but this authorization does not always require a traditional paper prescription from an outside doctor. Surgery Center of Pottsville offers a legal and structured solution for acquiring Zyban without a formal prescription: a streamlined, clinician‑guided assessment on site or via telehealth that, when appropriate, results in authorized dispensing through the center or a partner pharmacy. This service follows applicable laws, uses standardized screening for contraindications and interactions, verifies ID, and serves adults only. Availability varies by state and clinical judgment, and it is not appropriate for emergency needs. Pricing transparency, privacy safeguards, and follow‑up support are built in. If Zyban is unsuitable, the clinician will recommend alternatives, such as nicotine replacement, varenicline, or behavioral programs. Patients receive education on Zyban dosage, side effects, and interactions, with instructions for when to seek care and ways to maximize quit success through counseling and monitoring, and periodic blood pressure checks.
Zyban is a prescription form of bupropion sustained-release designed for smoking cessation. It reduces nicotine cravings and withdrawal by modulating dopamine and norepinephrine and partially blocking nicotinic receptors, making it easier to stop smoking.
Zyban roughly doubles the chances of long-term abstinence compared to placebo when combined with behavioral support. Success improves further with counseling, a set quit date, and adherence to the full course.
Most adults start with 150 mg once daily for 3 days, then increase to 150 mg twice daily at least 8 hours apart. Begin the medicine 1–2 weeks before your quit date to allow it to build up and reduce cravings.
Pick a quit date during the second week of treatment, typically days 8–14. Continue taking Zyban as directed after your quit date to help prevent relapse.
Most people use Zyban for 7–12 weeks. Some may benefit from extending treatment for relapse prevention, based on clinician guidance and progress.
The most common are insomnia, dry mouth, headache, nausea, anxiety, and tremor. Taking the second dose earlier in the afternoon and avoiding bedtime dosing can help with sleep disruption.
Zyban can rarely cause seizures, with risk increasing at higher doses or with certain conditions or substances. High blood pressure, especially when combined with nicotine replacement, and rare allergic reactions are possible; seek urgent care for severe symptoms.
Avoid Zyban if you have a seizure disorder, a current or past eating disorder (bulimia or anorexia), are abruptly stopping alcohol/benzodiazepines/sedatives, took an MAOI in the past 14 days, or are already on another bupropion product. Discuss risks if you have significant liver disease, bipolar disorder, or uncontrolled hypertension.
Yes, combining Zyban with nicotine replacement therapy (NRT) can improve quit rates, though blood pressure should be monitored. Your clinician can tailor the right combo and dosing plan.
Skip the missed dose if it’s close to your next dose and resume your regular schedule. Do not double up, as this increases seizure risk.
Zyban may help limit post-cessation weight gain, a common concern when quitting smoking. Healthy eating and activity remain important for weight management.
Limit or avoid alcohol because it can increase seizure risk and worsen side effects. Sudden heavy drinking or abrupt alcohol withdrawal while on Zyban is particularly risky.
Zyban contains bupropion, which is also used for depression, but you should not duplicate therapy with other bupropion products. Zyban strongly inhibits CYP2D6, so your clinician should check for interactions with other antidepressants and adjust doses as needed.
Zyban is not nicotine and is not considered addictive. It does not produce nicotine-like reinforcement or withdrawal when stopped.
Data are limited; decisions should be individualized by weighing quitting benefits against potential risks. Nicotine replacement in pregnancy is often preferred under supervision; discuss options with your obstetric clinician.
Many people notice fewer cravings and improved control within 1–2 weeks. This is why treatment starts before the quit date.
Zyban is generally prescribed for adults; evidence in adolescents is limited, and use should be guided by a specialist. Behavioral support is essential for younger people trying to quit.
Bupropion does not cause physical dependence, and many people can stop without tapering. Your clinician may suggest a short taper based on your response and side effects.
Zyban inhibits CYP2D6, raising levels of medications like certain SSRIs, SNRIs, tricyclics, antipsychotics, beta-blockers, and tamoxifen (which may be less effective). Avoid MAOIs, use caution with other seizure-threshold–lowering drugs (tramadol, stimulants), and discuss ritonavir, efavirenz, and other CYP2B6 modifiers with your prescriber.
Both contain bupropion; Zyban is labeled for smoking cessation, while Wellbutrin is for depression and seasonal affective disorder. Dosing, indications, and insurance coverage may differ; do not combine them.
Varenicline generally produces higher quit rates than Zyban in head-to-head studies. However, Zyban can be a strong alternative if varenicline is not tolerated, contraindicated, or unavailable.
Both improve quit rates versus no medication; patches deliver steady nicotine to ease withdrawal, while Zyban reduces cravings via non-nicotine mechanisms. Some people benefit most from using Zyban plus a patch under medical guidance.
Gum and lozenges provide on-demand nicotine for breakthrough cravings, while Zyban is taken on a schedule. Many quit plans pair Zyban with a long-acting patch and add gum/lozenges for spikes in cravings.
Combination NRT often outperforms single-form NRT and can be similar to or slightly less effective than varenicline. Zyban can be used with combination NRT for an additive effect when appropriate.
Adding a patch to Zyban can further improve abstinence rates, though monitoring blood pressure is important. This approach works best alongside structured behavioral support.
Cytisine (available in some countries) is a partial nicotinic agonist like varenicline and has shown superiority to NRT in trials. Direct comparisons with Zyban are limited, but cytisine and varenicline often yield higher quit rates than bupropion in network analyses.
Both can aid cessation; nortriptyline is used off-label and may be helpful when other options fail, but its anticholinergic side effects and cardiac risks limit use. Zyban is typically preferred due to a more favorable tolerability profile.
Nasal spray and inhaler deliver rapid nicotine relief for acute cravings. Zyban provides background control of withdrawal; people with strong cue-triggered urges may prefer adding a fast-acting NRT to Zyban.
Generic bupropion SR is bioequivalent to Zyban when sourced from reputable manufacturers. Many patients use generic bupropion SR for smoking cessation at the same doses, guided by a clinician.
The active ingredient and SR formulation are the same, but Zyban is specifically labeled for quitting smoking. If you’re already on Wellbutrin SR, your clinician can adjust dosing and counseling to support cessation without duplicating bupropion.
Zyban commonly causes insomnia, dry mouth, and anxiety; seizure risk is rare but dose-related. Varenicline more often causes nausea and vivid dreams; both carry warnings about neuropsychiatric symptoms, though large studies show they’re generally safe with monitoring.
Zyban has modest benefits in limiting weight gain after cessation, while NRT’s effect is neutral to modest. If weight is a major concern, Zyban or combining NRT forms with dietary strategies can help.
Clonidine is an off-label option that can reduce withdrawal but is limited by side effects like sedation and low blood pressure. Zyban usually offers a better balance of efficacy and tolerability.
Both are effective and generally safe with monitoring, and large trials have not shown increased serious neuropsychiatric events versus NRT or placebo. Choice depends on prior response, side-effect profiles, and interaction with current psychiatric medications.
E-cigarettes are not a medication and evidence is mixed; some people quit with them, but they carry their own risks. Clinically tested options like Zyban, varenicline, and NRT have stronger, standardized evidence and dosing guidance.